Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK,

  Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and
Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and
                               Align Technology

PR Newswire

NEW YORK, December 5, 2013

NEW YORK, December 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Becton,
Dickinson and Company (NYSE: BDX), Sanofi SA (NYSE: SNY), GlaxoSmithKline plc
(NYSE: GSK), Agilent Technologies Inc. (NYSE: A), and Align Technology Inc.
(NASDAQ: ALGN). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Becton, Dickinson and Company Research Report

On November 26, 2013, Becton, Dickinson and Company (BD) reported that its
Board of Directors declared a quarterly dividend of 54.5 cents per common
share, indicating an increase of 5 cents per share, or approximately 10% QoQ.
BD stated that the dividend is payable on December 31, 2013 to holders of
record on December 10, 2013. The Company added that at the current rate, the
annual dividend for FY 2014 would be $2.18 per share. Vincent A. Forlenza,
Chairman, CEO and President, commented, "This is the forty-second consecutive
fiscal year in which we have raised our dividend. This increase reflects our
confidence in our long-term outlook, as well as our ongoing commitment of
returning value to our shareholders." The Full Research Report on Becton,
Dickinson and Company - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:



Sanofi SA Research Report

On November 25, 2013, Sanofi SA (Sanofi), along with Regeneron
Pharmaceuticals, Inc. (Regeneron), announced that the Phase 2a study of
dupilumab in asthma was selected as "Clinical Advance of the Year" by Scrip
Intelligence at the 9^th annual Scrip Awards, announced by Scrip- a leading

industry publication. The Company informed that Dupilumab, which is being
developed by Sanofi and Regeneron, is a fully-human monoclonal antibody that
is in clinical development to cure asthma, atopic dermatitis, and nasal
polyposis. George D. Yancopoulos, M.D., Ph.D., President, Regeneron
Laboratories and Chief Scientific Officer, commented, "We appreciate the
recognition by Scrip that dupilumab is one of the most exciting emerging
clinical candidates in the industry." The Full Research Report on Sanofi SA -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:



GlaxoSmithKline plc Research Report

On November 28, 2013, GlaxoSmithKline plc (GSK) announced that the European
Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is
recommending marketing authorization for a two-dose schedule in 9-14 year old
girls for its cervical cancer vaccine, Cervarix™ [Human papillomavirus
bivalent (types 16 and 18) vaccine, recombinant]. Thomas Breuer, Senior Vice
President and Lead Physician, GSK Vaccines, commented, "We are delighted by
the positive opinion issued by CHMP on a two-dose schedule for Cervarix. It
represents another major milestone in our commitment to reducing the global
burden of cervical cancer which remains high. Many countries are unable to
implement national immunisation programmes in young adults with high coverage.
A two-dose vaccine schedule has the potential to be easier to deliver than a
three-dose schedule, thereby expanding the population that could benefit from
protection." The Company added that a CHMP positive opinion is one of the last
steps before marketing authorization is received from European Commission, but
does not always result in marketing authorizations. The Full Research Report
on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:



Agilent Technologies Inc. Research Report

On November 22, 2013, Agilent Technologies Inc. (Agilent) announced that its
Board of Directors has authorized a new share repurchase program, which will
be effective once the Company's current $1 billion repurchase program
concludes. The Company stated that the new repurchase program is intended to
reduce or eliminate dilution which results from stock issuances under the
Company's employee equity incentive programs for maintaining a share count of
about 335 million diluted shares. Agilent added that the Board has also
approved a 10% increase in the quarterly dividend to $0.132 per share, to be
paid on January 22, 2014, to stockholders of record as of the close of
business on December 31, 2013. The Full Research Report on Agilent
Technologies Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:



Align Technology Inc. Research Report

On December 2, 2013, Align Technology Inc. (Align) announced that it has
extended its funding of the Align Research Award Program for the fifth
straight year for universities in North America and for a fourth year for
international universities. Align stated that it has also added two additional
research awards to the international segment due to the rise in university
research in programs outside of North America. The Company informed that the
Align Research Award Program is an annually-funded program for promoting
clinical and scientific research in clear aligner therapy. John Morton,
Align's Director of Research and Technology, commented, "Study results from
past awards have increased our understanding of treatment using clear
aligners. In light of this success, we are excited to increase the number of
research grants that may be funded this year." The Company informed that it
has a total award pool of $325,000 for 2014. The Full Research Report on Align
Technology Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:




1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA


SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.